Spondyloarthritis & psoriatic arthritis
Variability of Psoriatic Arthritis Impact of Disease questionnaire (PsAID12) thresholds in psoriatic arthritis: data from the ReFlaP study
Authors' conclusion
This study established cutoffs for PsAID12 in a clinical practice observational population, corresponding to remission and varying levels of disease impact.
Study context
- Population
- Patients with Psoriatic Arthritis (PsA), ReFlaP study (observational, clinical practice setting)analysed
- Participants
- 410 patients
- Outcome
- PsAID12 cutoffs defining disease impact states (remission, low, moderate, high impact) against disease activity measures
- Follow-up
- Baseline
Methodological detailsbaseline data of an observational, prospective, multicentre, international study, Youden's index and 75th percentile method, ROC curve analyses
- Baseline data of an observational, prospective, multicentre, international study
- Youden's index and 75th percentile method
- ROC curve analyses
Main finding
As reported in the abstract
PsAID12 cutoffs using DAPSA as external anchor
- Remission
- <1.7
- Low impact
- ≥1.7 to ≤3.1
- Moderate impact
- >3.1 to <4.8
- High impact
- ≥4.8
- AUC of PsAID12 against external anchors
- 0.75 to 0.94
Observational data: associations, not effects.
Further findings
PsAID12 score · baseline
- Mean (s.d.) PsAID12 score
- 3.4 (2.5)
Prevalence of remission and low disease activity across anchors · baseline
- Remission prevalence range
- 12.4% to 36.1%
- Low disease activity prevalence range
- 37.8% to 59.8%
PsAID12 performance vs external anchors (AUC) · baseline
- AUC range
- 0.75 to 0.94
- Patient and physician opinions performed less stringently than composite scores
Original publication
Variability of Psoriatic Arthritis Impact of Disease questionnaire (PsAID12) thresholds in psoriatic arthritis: data from the ReFlaP study. Rheumatology (Oxford). Published 3 January 2025. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →